Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain's ability to compensate for damage due to trauma or disease. The Company's PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone215-944-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions
What is Helius Medical Technologies' stock symbol?
Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."
How were Helius Medical Technologies' earnings last quarter?
Helius Medical Technologies Inc (OTCMKTS:HSDT) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.02. The business earned $0.48 million during the quarter. View Helius Medical Technologies' Earnings History.
What guidance has Helius Medical Technologies issued on next quarter's earnings?
Helius Medical Technologies issued an update on its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1-2 million.
What price target have analysts set for HSDT?
2 Wall Street analysts have issued 1-year target prices for Helius Medical Technologies' shares. Their predictions range from $10.00 to $14.00. On average, they anticipate Helius Medical Technologies' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for Helius Medical Technologies.
What is the consensus analysts' recommendation for Helius Medical Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Helius Medical Technologies.
Has Helius Medical Technologies been receiving favorable news coverage?
Media stories about HSDT stock have trended positive this week, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Helius Medical Technologies earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of Helius Medical Technologies' key competitors?
Some companies that are related to Helius Medical Technologies include BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Cutera (CUTR), Electrocore (ECOR), Zynex (ZYXI), Fonar (FONR), Stereotaxis (STXS), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), Edap Tms (EDAP), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Viveve Medical (VIVE) and ENDRA Life Sciences (NDRA).
What other stocks do shareholders of Helius Medical Technologies own?
Who are Helius Medical Technologies' key executives?
Helius Medical Technologies' management team includes the folowing people:
- Philippe Deschamps, President, Chief Executive Officer, Director
- Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
- Brian Bapty, Vice President, Strategy and Business Development
- Jonathan Sackier, Chief Medical Officer
- Dane Andreeff, Director
- Huaizheng Peng, Director
- Mitch Eugene Tyler, Director
- Thomas E. Griffin, Independent Director
- Edward M. Straw, Independent Director
Who are Helius Medical Technologies' major shareholders?
Helius Medical Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.53%), Pembroke Management LTD (3.12%), Polar Capital LLP (1.57%), Isthmus Partners LLC (0.81%), Northern Trust Corp (0.80%) and Geode Capital Management LLC (0.72%). Company insiders that own Helius Medical Technologies stock include Blane Walter, Dane Andreeff, Joyce N Laviscount, Philippe Deschamps and Thomas E Griffin. View Institutional Ownership Trends for Helius Medical Technologies.
Which major investors are selling Helius Medical Technologies stock?
Which major investors are buying Helius Medical Technologies stock?
HSDT stock was bought by a variety of institutional investors in the last quarter, including Polar Capital LLP, BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Northern Trust Corp, Scotia Capital Inc., Rhumbline Advisers and Bank of New York Mellon Corp. Company insiders that have bought Helius Medical Technologies stock in the last two years include Blane Walter, Dane Andreeff, Joyce N Laviscount, Philippe Deschamps and Thomas E Griffin. View Insider Buying and Selling for Helius Medical Technologies.
How do I buy shares of Helius Medical Technologies?
Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Helius Medical Technologies' stock price today?
One share of HSDT stock can currently be purchased for approximately $6.80.
How big of a company is Helius Medical Technologies?
Helius Medical Technologies has a market capitalization of $159.00 million.
What is Helius Medical Technologies' official website?
How can I contact Helius Medical Technologies?
Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]
MarketBeat Community Rating for Helius Medical Technologies (OTCMKTS HSDT)
MarketBeat's community ratings are surveys of what our community members think about Helius Medical Technologies and other stocks. Vote "Outperform" if you believe HSDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
